What Regenesome does

Regenesome Inc. (リジェネソーム株式会社) is a Tokyo-based longevity biotechnology venture founded on July 12, 2024, as a wholly-owned subsidiary of Space Seed Holdings Co., Ltd. The company develops anti-aging biotechnologies built around exosome analysis, nanoparticle engineering, and hypoxic environment research, with stated ambitions to contribute to lunar habitation by 2040. Its product pipeline includes Vicell, a nanoparticle-based supplement designed for intranasal and oral brain delivery; SakeSome, sake-derived 1-500nm nanoparticles shown to activate B and T cells; and a broader line of exosome-based supplements, foods, and cosmetics. A second technology track targets gene therapy manufacturing via a co-developed ergothioneine-based method for enhancing AAV viral vector productivity.

The company's underlying platform integrates molecular biology, fermentation-derived nanotechnology, and epigenetic clock measurement into a multi-domain intervention framework. Research collaborations underpin the technology base: joint work with Tokyo University of Science produced the sake-nanoparticle immunology patent; a Tohoku University affiliation supports mitochondrial activation research via hypoxic environments; and a partnership with University of Tokyo neurotech startup FastNeura (announced March 2026) extends the platform into EEG-measured cognitive assessment for office wellness applications. Two pending joint patents, one with Good Hero Therapeutics and Euglena Co. and one with Tokyo University of Science, anchor the IP position, though neither has yet been granted.

Regenesome operates as a B2B research-driven venture with three theoretical revenue streams: commercialization of exosome-based consumer products, licensing of longevity-related IP, and consulting services for management, sales, and R&D operations. Pricing is not publicly disclosed and no customer logos or revenue figures are available. Go-to-market is sales-led through research collaborations and co-development agreements rather than direct enterprise sales, and the company has raised approximately $666K across two small seed rounds (Japan System Techniques in October 2024 and Leave a Nest Capital in September 2025) in addition to parent company funding.

Name

Regenesome

Legal name

リジェネソーム株式会社

Website

https://regenesome.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Regenesome is a Tokyo-based longevity biotech venture developing exosome-based supplements, sake-derived nanoparticle immune activators, and AAV viral vector manufacturing technologies through B2B research collaborations and joint patent filings with academic and industry partners.

Ownership category

akta.pro rank

Product category

Longevity Biotechnology

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Exosome biotechnology
• Nanoparticle supplements
• Longevity therapeutics
• Anti-aging research
• Gene therapy manufacturing

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Exosome-based Products: Development and potential commercialization of supplements, foods, and cosmetics utilizing exosomes. Also includes development of new products and services utilizing substances contained in other cells.
2. Licensing and IP Management: Intellectual property management including patents for virus vector production enhancement, immune cell activation, and other longevity-related technologies.
3. Consulting Services: Consulting services for management, sales, research and development operations related to longevity and anti-aging biotechnology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Regenesome (リジェネソーム株式会社) is a longevity biotechnology venture that develops exosome-based supplements, foods, and cosmetics for anti-aging applications, combined with proprietary nanoparticle technology (Vicell for brain-targeted delivery, sake-derived nanoparticles for immune cell activation) and hypoxic environment technology. The company also conducts research into viral vector productivity enhancement for gene therapy manufacturing and offers consulting and intellectual property management services in longevity biotechnology.

Product overview

Regenesome is a longevity biotech venture developing a portfolio of nanoparticle-based health products. The core offering centers on exosome-based supplements, foods, and cosmetics targeting anti-aging and healthspan extension. Key product lines include Vicell (brain-targeting nanoparticle supplements for cognitive and longevity applications) and SakeSome (Japanese sake-derived nanoparticle immune cell activators). The company combines these products with hypoxic environment technology and epigenetic clock measurement to build a personalized multi-domain intervention platform. All products are developed through the company's molecular biology and nanotechnology capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Vicell Nanoparticle-based supplement technology designed for brain delivery via nasal and oral administration, used in combination with hypoxic environment technology and epigenetic clocks for personalized multi-domain interventions targeting cognitive function and longevity.
• SakeSome (Sake-derived Nanoparticle Ingredient) Japanese sake-derived nanoparticle ingredient (1-500nm diameter) containing sugar-protein aggregates from yeast and koji mold, developed through parallel secondary fermentation. Confirmed to activate immune cells (B cells and T cells) and intended for application in regenerative medicine and immune maintenance.
• Exosome-based supplements, foods, and cosmetics Products utilizing exosomes (extracellular vesicles) for anti-aging, regenerative medicine solutions, and longevity applications, developed through detailed exosome analysis and molecular nanotechnology design.
• Ergothioneine-based Virus Vector Productivity Enhancement Technology Technology that enhances virus vector productivity by adding the antioxidant amino acid ergothioneine to cell culture systems, with demonstrated improved viral titers after 72 hours of culture compared to control groups. Developed for gene therapy manufacturing applications.
• Hypoxic Environment Cognitive Assessment Technology Scientific evaluation of hypoxic environments on cognitive function through EEG measurements, analyzing brain wave signal fluctuations and task accuracy changes during cognitive N-back tasks under normoxic and hypoxic conditions. Designed for application in office wellness programs and personalized multi-domain intervention platforms.

Quantifiable outcome

• Improved viral titers after 72 hours of culture with ergothioneine addition compared to control groups
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• FastNeura Inc.coreStrategic or Co-development Partner · 25 March 2026Neurotech startup from University of Tokyo's Faculty of Medicine conducting collaborative research on the effects of hypoxic environments on cognitive function through EEG measurements. Research involves cognitive N-back tasks under normoxic and hypoxic conditions using Open BCI Cyton Board devices. Aims to apply findings to office wellness programs and develop personalized multi-domain intervention platforms.
• Good Hero Therapeutics Inc.coreStrategic or Co-development Partner · 23 March 2026Gene therapy company with innovative foundational technologies in the field. Joint patent application filed for ergothioneine-based virus vector productivity enhancement technology. Regenesome supports GHT's development of gene therapeutic manufacturing processes using the patented technology. GHT has been selected for national support programs.
• Euglena Co., Ltd.coreStrategic or Co-development Partner · 23 March 2026Biotechnology company providing candidate substances with potential for improving AAV vector production. Participated in joint patent application for ergothioneine-based virus vector productivity enhancement technology alongside Regenesome and Good Hero Therapeutics.
• Tokyo University of Science (東京科学大学)coreStrategic or Co-development Partner · 26 December 2025National university with International Center for Biomedical Engineering Research. Joint research with Regenesome discovered immune cell activation functions in sake-derived nanoparticles. Resulted in patent application for immune cell activators and activation methods using 1-500nm nanoparticles containing sugar-protein aggregates from yeast and koji mold.
• Space Seed Holdings Co., Ltd.flagshipOthersParent company of Regenesome. Participates in Space Food Sphere project exploring new possibilities of space food (since April 2024) and XPRIZE Healthspan global competition focused on extending human healthspan (since May 2024). Provides research network and deep knowledge in space and life sciences.
• Tohoku UniversitycoreStrategic or Co-development PartnerAcademic partnership for multifaceted research including mitochondrial activation through hypoxic environments. Regenesome's CEO Kengo Suzuki serves as Visiting Professor at Tohoku University Graduate Program for Frontier Medical Sciences.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Euglena Co., Ltd. Japanese microalgae-based biotech co-founded by Regenesome's CEO Kengo Suzuki in 2005. Operates in health foods, cosmetics, and biofuel — a direct comparable for a Japan-anchored, founder-led biotech commercializing biologically derived health products to consumer markets.

Broad incumbents

• Elysium Health: US-based longevity supplement company founded by MIT scientists, commercializing NAD+ and other cellular health products. Comparable in the consumer longevity supplement space and in its emphasis on scientific legitimacy for aging interventions.
• Calico Life Sciences: Alphabet-backed longevity research company pursuing fundamental biology of aging. Relevant as a well-resourced industry incumbent in the broader longevity R&D category, though operating at much larger scale.
• Unity Biotechnology: Publicly listed senescence-focused longevity biotech developing therapeutics targeting aging cells. Comparable in cellular senescence / aging biology focus, though at a far more advanced clinical stage.

Emerging players

• Altos Labs: Well-capitalized (~$3B raised) longevity biotech pursuing cellular rejuvenation programming. Relevant peer in the longevity biotech category and in its pursuit of epigenetic and cellular reprogramming approaches to healthspan extension.
• Insilico Medicine: AI-driven longevity and drug discovery biotech with a pipeline of aging-related therapeutics. Comparable in pursuing technology-enabled longevity interventions, though focused on pharmaceutical rather than consumer delivery formats.
• Turn Biotechnologies: US-based cellular rejuvenation company developing mRNA-based epigenetic reprogramming therapies. Directly comparable technology platform (epigenetic reprogramming) and overlap with regenerative medicine and exosome-adjacent delivery science.
• ExoCoBio: South Korea-based exosome therapeutics and cosmetic company. Closest direct peer in commercializing exosome-derived products for regenerative and cosmetic applications in the Asian market.
• Loyal for Dogs: Veterinary longevity biotech developing drugs to extend dog healthspan, with FDA engagement. Comparable in its science-driven, regulator-engaged approach to commercializing longevity interventions, though in the veterinary category.

Others

• Good Hero Therapeutics: Tokyo-based gene therapy company and direct joint patent partner with Regenesome on ergothioneine-based AAV productivity enhancement. Closely tied via co-developed IP and capital/business alliance, making it a meaningful ecosystem participant rather than a competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenesome